Abivax (ABVX) Accounts Payables (2021 - 2026)

Abivax's Accounts Payables history runs 6 years deep, the most recent figure standing at $34.6 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 41.89% year-over-year to $34.6 million in Q1 2026; TTM through Mar 2026 was $34.6 million, a 41.89% decrease from a year earlier, with the FY2025 full-year figure at $43.7 million, down 7.84% from the prior year.
• Accounts Payables retreated to $34.6 million in Q1 2026 per ABVX's latest filing, from $43.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $65.1 million in Q2 2025 and bottomed at $15.8 million in Q4 2022.
• The 5-year median for Accounts Payables is $43.7 million (2025), against an average of $42.8 million.
• Across the five-year window, Accounts Payables jumped 221.8% in 2023 and plunged 41.89% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $15.8 million in 2022, then soared by 221.8% to $50.8 million in 2023, then decreased by 7.83% to $46.8 million in 2024, then dropped by 6.66% to $43.7 million in 2025, then declined by 20.95% to $34.6 million in 2026.
• Per Business Quant, the three latest ABVX Accounts Payables figures stand at $34.6 million (Q1 2026), $43.7 million (Q4 2025), and $35.1 million (Q3 2025).